Midatech Appoints RBC as Joint Broker

9 December 2015

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech Appoints RBC as Joint Broker

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the specialty pharmaceutical company focused on the development and commercialisation of multiple therapeutic products, is pleased to announce the appointment of RBC Europe Limited as Joint Broker to the Company with immediate effect. Panmure Gordon (UK) Limited will continue to act as Nominated Adviser and Joint Broker.

- Ends -

For more information, please contact:

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Corporate Finance

Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

RBC Europe Limited (Joint Broker)

Darrell Uden / Paul Tomasic / Rupert Walford / Thomas Stockman

Tel: +44 (0)207 653 4000

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: [email protected]

About Midatech Pharma PLC

Midatech is a nanomedicine company focused on the development and commercialisation of multiple therapeutic products, using its nanomedicine and sustained release technologies, to enhance the delivery of medicines in major diseases with high unmet medical need. These diseases include diabetes, certain cancers, such as liver, ovarian and brain (glioblastoma) and neurological/ophthalmologic conditions.

Midatech's strategy is to develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

All of Midatech's product candidates derive from its two multi-applicable platform technologies that can be used alone or in combination to enable the targeted delivery ('right place') and sustained release ('right time') of existing drugs.

Midatech's core technology platform is a drug conjugate delivery system based on a patented form of gold nanoparticles (GNP) that are developed to improve key parameters of existing and new drugs for the safe and targeted release of therapeutic payloads at specific organs, cells or sites of disease.

Midatech's secondary platform of sustained release technology (acquired through its acquisition of Q Chip Limited in 2014) involves the consistent and precise encapsulation of active drug compounds within polymer microspheres enabling their release into the body in a highly controlled manner over a prolonged period of time.

Midatech closed the acquisition of DARA BioSciences Inc., an oncology supportive care pharmaceutical company, on 7 December 2015, adding an oncology-focused commercial platform and products in the US. Midatech's American Depositary Shares, delivered to former DARA stockholders, trade on the NASDAQ Capital Market in the United States under the symbol MTP.

Midatech is headquartered near Oxford, UK, with a nanoparticle manufacturing operation in Bilbao, Spain and an R&D facility in Cardiff, UK.

For further company information see: www.midatechgroup.com.